Advances in Experimental Animal Models of Hepatocellular Carcinoma

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 May 30

PMID 37248746

Authors

Jing Li

Xin Wang

Mudan Ren

Shuixiang He

Yan Zhao

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a common malignant tumor with insidious early symptoms, easy metastasis, postoperative recurrence, poor drug efficacy, and a high drug resistance rate when surgery is missed, leading to a low 5-year survival rate. Research on the pathogenesis and drugs is particularly important for clinical treatment. Animal models are crucial for basic research, which is conducive to studying pathogenesis and drug screening more conveniently and effectively. An appropriate animal model can better reflect disease occurrence and development, and the process of anti-tumor immune response in the human body. This review summarizes the classification, characteristics, and advances in experimental animal models of HCC to provide a reference for researchers on model selection.

Citing Articles

infection downregulates hypoxia‑inducible factor 1α expression to suppress the vascularization and tumorigenesis of liver cancer.

Wu R, Chen X, Chen H, Li M, Liang Y Oncol Lett. 2024; 28(6):604.

PMID: 39483968 PMC: 11525613. DOI: 10.3892/ol.2024.14737.

FIGNL1 Promotes Hepatocellular Carcinoma Formation Remodeling ECM-receptor Interaction Pathway Mediated by HMMR.

Wang J, Sun L, Liu Y, Zhang Y Curr Gene Ther. 2023; 24(3):249-263.

PMID: 37929733 PMC: 11071652. DOI: 10.2174/0115665232274223231017052707.

Emerging and potential use of CRISPR in human liver disease.

Adlat S, Vazquez Salgado A, Lee M, Yin D, Wangensteen K Hepatology. 2023; .

PMID: 37607734 PMC: 10881897. DOI: 10.1097/HEP.0000000000000578.

Advances in experimental animal models of hepatocellular carcinoma.

Li J, Wang X, Ren M, He S, Zhao Y Cancer Med. 2023; 12(14):15261-15276.

PMID: 37248746 PMC: 10417182. DOI: 10.1002/cam4.6163.

References

Zhang C, Gao Y, Du C, Markowitz G, Fu J, Zhang Z . Hepatitis B-Induced IL8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation. Cancer Res. 2021; 81(9):2386-2398. DOI: 10.1158/0008-5472.CAN-20-3453. View

Hu B, Li H, Guo W, Sun Y, Zhang X, Tang W . Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int J Cancer. 2019; 146(6):1606-1617. DOI: 10.1002/ijc.32564. View

Heindryckx F, Colle I, Van Vlierberghe H . Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009; 90(4):367-86. PMC: 2741148. DOI: 10.1111/j.1365-2613.2009.00656.x. View

Gnatenko D, Xu X, Zhu W, Schmidt V . Transcript profiling identifies iqgap2(-/-) mouse as a model for advanced human hepatocellular carcinoma. PLoS One. 2013; 8(8):e71826. PMC: 3741273. DOI: 10.1371/journal.pone.0071826. View

Broadfield L, Duarte J, Schmieder R, Broekaert D, Veys K, Planque M . Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis. Cancer Res. 2021; 81(8):1988-2001. PMC: 7611295. DOI: 10.1158/0008-5472.CAN-20-1954. View

Teufel A, Itzel T, Erhart W, Brosch M, Wang X, Kim Y . Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. Gastroenterology. 2016; 151(3):513-525.e0. DOI: 10.1053/j.gastro.2016.05.051. View

Ou D, Lin Y, Hsu C, Lin Y, Chen C, Yu J . Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer. 2019; 8(3):155-171. PMC: 6547269. DOI: 10.1159/000489318. View

Geraud C, Mogler C, Runge A, Evdokimov K, Lu S, Schledzewski K . Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival. Liver Int. 2013; 33(9):1428-40. DOI: 10.1111/liv.12262. View

Chang C, Chen Y, Huang K, Cheng H, Chan S, Tai K . Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology. 2007; 45(3):746-54. DOI: 10.1002/hep.21560. View

10.

Rebouissou S, Nault J . Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020; 72(2):215-229. DOI: 10.1016/j.jhep.2019.08.017. View

11.

Tsai W, Hsu S, Hsu C, Lai T, Chen S, Shen R . MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122(8):2884-97. PMC: 3408747. DOI: 10.1172/JCI63455. View

12.

McGlynn K, Hunter K, Levoyer T, Roush J, Wise P, Michielli R . Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res. 2003; 63(15):4594-601. View

13.

Yan C, Yang Q, Huo X, Li H, Zhou L, Gong Z . Chemical inhibition reveals differential requirements of signaling pathways in kras- and Myc-induced liver tumors in transgenic zebrafish. Sci Rep. 2017; 7:45796. PMC: 5381109. DOI: 10.1038/srep45796. View

14.

Wang C, Tang H, Geng A, Dai B, Zhang H, Sun X . Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors. Proc Natl Acad Sci U S A. 2020; 117(42):26356-26365. PMC: 7584895. DOI: 10.1073/pnas.2002917117. View

15.

Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, Blankenstein T . Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest. 2013; 123(3):1032-43. PMC: 3582129. DOI: 10.1172/JCI64742. View

16.

Finnberg N, Stenius U, Hogberg J . Heterozygous p53-deficient (+/-) mice develop fewer p53-negative preneoplastic focal liver lesions in response to treatment with diethylnitrosamine than do wild-type (+/+) mice. Cancer Lett. 2004; 207(2):149-55. DOI: 10.1016/j.canlet.2003.11.013. View

17.

Hussain S, Schwank J, Staib F, Wang X, Harris C . TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007; 26(15):2166-76. DOI: 10.1038/sj.onc.1210279. View

18.

Lee J, Chu I, Mikaelyan A, Calvisi D, Heo J, Reddy J . Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004; 36(12):1306-11. DOI: 10.1038/ng1481. View

19.

Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwalder M, Tacke F . Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022; 77(4):1136-1160. DOI: 10.1016/j.jhep.2022.06.012. View

20.

Winer B, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low B, Johnson H . Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med. 2018; 10(447). PMC: 6337727. DOI: 10.1126/scitranslmed.aap9328. View